Treatment success Fair, good or excellent effectiveness · Adults with lateral elbow pain
Topical NSAIDs may leads to higher treatment success Fair, good or excellent effectiveness compared with placebo (low certainty).
1 finding from 1 review
Function/disability · Adults with lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · Adults with lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Adults with lateral elbow pain
1 finding from 1 review
Adverse events · Adults with lateral elbow pain
Topical NSAIDs showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Pain 0 to 100 visual analogue scale and 10‐point Likert scale (lower score = less pain) · Adults with lateral elbow pain
1 finding from 1 review
Treatment success Fair, good or excellent effectiveness · Adults with lateral elbow pain
Oral NSAIDs showed no clear difference in treatment success Fair, good or excellent effectiveness compared with placebo (low certainty).
1 finding from 1 review
Quality of life · Adults with lateral elbow pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
ALS Functional Rating Scale (ALSFRS) score at 3 months Scale from: 0 to 40 (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Intervention not reported
Short‐Form‐36 Health Survey (SF‐36) score at 3 months Scale from: 0 to 100 (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Intervention not reported
Fatigue Severity Scale score at 3 months Scale from: 0 to 63 (lower is better). · people with amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Intervention not reported
Manual Muscle Testing score at 3 months Right and left shoulder abduction, elbow flexion and extension, finger abduction and extension, hip flexion, knee flexion and extension, foot dorsiflexion and plantarflexion assessed and graded 0 to 5 Medica... · people with amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Intervention not reported
Upper extremity maximum voluntary isometric contraction score at 3 months Quantitative Muscle Assessment (QMA) system. Data were normalized, summed and averaged to yield an U/E megascore (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Intervention not reported
Lower extremity maximum voluntary isometric contraction score at 3 months Quantitative Muscle Assessment (QMA) system. Data were normalized, summed and averaged to yield a L/E megascore (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Intervention not reported
Adverse effects related to the intervention · people with amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Changes to the ALSFRS‐R scores at 12 months · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Muscle strength · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Changes to FSS at 12 months · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Withdrawals due to adverse events · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease
1 finding from 1 review
Intervention not reported
rhIGF‐I, 0.1 mg/kg/day ‐ survival at12 months · patients with amyotrophic lateral sclerosis/motor neuron disease
1 finding from 1 review